{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:44:31Z","timestamp":1773294271155,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,3,28]],"date-time":"2003-03-28T00:00:00Z","timestamp":1048809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1007\/s00213-003-1418-x","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T18:25:12Z","timestamp":1478975112000},"page":"315-323","source":"Crossref","is-referenced-by-count":29,"title":["A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens"],"prefix":"10.1007","volume":"167","author":[{"given":"Zhu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,3,28]]},"reference":[{"key":"1418_CR1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0361-9230(86)90181-4","volume":"16","author":"Altar","year":"1986","unstructured":"Altar CA, Wasley AM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in ray brain. Brain Res Bull 16:517\u2013525","journal-title":"Brain Res Bull"},{"key":"1418_CR2","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/0024-3205(84)90540-X","volume":"35","author":"Billard","year":"1984","unstructured":"Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984) Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci 35:1885\u20131893","journal-title":"Life Sci"},{"key":"1418_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0920-9964(95)95477-Q","volume":"15","author":"Bligh-Glover","year":"1995","unstructured":"Bligh-Glover W, Jaskiw G, Vrtunski B, Ubogy D, Meltzer HY (1995) 5HT2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res 15:153\u2013154","journal-title":"Schizophr Res"},{"key":"1418_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0893-133X(02)00311-1","volume":"27","author":"Bonaccorso","year":"2002","unstructured":"Bonaccorso S, Meltzer H, Li Z, Dai J, Alboszta A, Ichikawa J (2002) SR46349-B, a 5-HT(2A\/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 27:430\u2013441","journal-title":"Neuropsychopharmacology"},{"key":"1418_CR5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1592\/phco.21.7.717.34575","volume":"21","author":"Carnahan","year":"2001","unstructured":"Carnahan RM, Lund BC, Perry PJ (2001) Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 21:717\u2013730","journal-title":"Pharmacotherapy"},{"key":"1418_CR6","first-page":"674","volume":"23","author":"Costall","year":"1973","unstructured":"Costall B, Naylor RJ (1973) Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung 23:674\u2013683","journal-title":"Arzneimittelforschung"},{"key":"1418_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0014-2999(79)90396-0","volume":"55","author":"Coupet","year":"1979","unstructured":"Coupet J, Rauh CE (1979) 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites. Eur J Pharmacol 55:215\u2013218","journal-title":"Eur J Pharmacol"},{"key":"1418_CR8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0033-3182(82)73416-4","volume":"23","author":"DePaulo","year":"1982","unstructured":"DePaulo J Jr, Ayd F (1982) Loxapine: fifteen years' clinical experience. Psychosomatics 23:261\u2013271","journal-title":"Psychosomatics"},{"key":"1418_CR9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","volume":"49","author":"Farde","year":"1992","unstructured":"Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538\u2013544","journal-title":"Arch Gen Psychiatry"},{"key":"1418_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4088\/JCP.v60n0112c","volume":"60","author":"Glazer","year":"1999","unstructured":"Glazer W (1999) Does loxapine have \"atypical\" properties? Clinical evidence. J Clin Psychiatry 60:42\u201346","journal-title":"J Clin Psychiatry"},{"key":"1418_CR11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","volume":"18","author":"Goff","year":"1998","unstructured":"Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296\u2013304","journal-title":"J Clin Psychopharmacol"},{"key":"1418_CR12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","volume":"76","author":"Ichikawa","year":"2001","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521\u20131531","journal-title":"J Neurochem"},{"key":"1418_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0893-133X(01)00312-8","volume":"26","author":"Ichikawa","year":"2002","unstructured":"Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002a) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neupsychopharmacology 26:325\u2013339","journal-title":"Neupsychopharmacology"},{"key":"1418_CR14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0006-8993(02)02544-1","volume":"939","author":"Ichikawa","year":"2002","unstructured":"Ichikawa J, Dai J, Meltzer HY (2002b) 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939:34\u201342","journal-title":"Brain Res"},{"key":"1418_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0006-8993(02)03692-2","volume":"958","author":"Ichikawa","year":"2002","unstructured":"Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY (2002c) Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 958:176\u2013184","journal-title":"Brain Res"},{"key":"1418_CR16","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/sj.bjp.0701975","volume":"124","author":"Kalkman","year":"1998","unstructured":"Kalkman HO, Neumann V, Hoyer D, Tricklebank MD (1998) The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550\u20131556","journal-title":"Br J Pharmacol"},{"key":"1418_CR17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/archpsyc.55.7.666","volume":"55","author":"Kapur","year":"1998","unstructured":"Kapur S, Zipursky RB (1998) Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy. Arch Gen Psychiatry 55:666\u2013668","journal-title":"Arch Gen Psychiatry"},{"key":"1418_CR18","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0893-133X(96)00100-5","volume":"15","author":"Kapur","year":"1996","unstructured":"Kapur S, Zipursky RB, Jones C, Remington GJ, Wilson AA, DaSilva J, Houle S (1996) The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 15:562\u2013566","journal-title":"Neuropsychopharmacology"},{"key":"1418_CR19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1176\/ajp.154.11.1525","volume":"154","author":"Kapur","year":"1997","unstructured":"Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S (1997) PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 154:1525\u20131529","journal-title":"Am J Psychiatry"},{"key":"1418_CR20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","volume":"140","author":"Keck","year":"1998","unstructured":"Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998) Ziprasidone 40 and 120\u00a0mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173\u2013184","journal-title":"Psychopharmacol"},{"key":"1418_CR21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","volume":"288","author":"Kuroki","year":"1999","unstructured":"Kuroki T, Meltzer HY, Icikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774\u2013781","journal-title":"J Pharmacol Exp Ther"},{"key":"1418_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-8993(02)02620-3","volume":"947","author":"Li\u00c3\u00a9geois","year":"2002","unstructured":"Li\u00e9geois J-F, Ichikawa J, Meltzer HY (2002) 5-HT2A receptor antagonism potentates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157\u2013162","journal-title":"Brain Res"},{"key":"1418_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s002130050265","volume":"131","author":"Lucas","year":"1997","unstructured":"Lucas G, Bonhomme N, De Deurwaerdere P, Le Moal M, Spampinato U (1997) 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A\/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131:57\u201363","journal-title":"Psychopharmacology"},{"key":"1418_CR24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","volume":"151","author":"Marder","year":"1994","unstructured":"Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825\u2013835","journal-title":"Am J Psychiatry"},{"key":"1418_CR25","unstructured":"Meltzer HY (1995) The concept of atypical antipsychotics. In: den Boer JA, Westenberg HGM, van Praag HM (eds) Advances in the neurobiology of schizophrenia, vol\u00a01. Wiley, Sussex, pp\u00a0265\u2013273"},{"key":"1418_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0006-3223(99)00255-3","volume":"46","author":"Meltzer","year":"1999","unstructured":"Meltzer HY (1999) Dopamine2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic? Biol Psychiatry 46:144\u2013149","journal-title":"Biol Psychiatry"},{"key":"1418_CR27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4088\/JCP.v60n0411c","volume":"60","author":"Meltzer","year":"1999","unstructured":"Meltzer HY, Jayathilake K (1999) Low-dose loxapine in the treatment of schizophrenia: is it more effective and more atypical than standard-dose loxapine? J Clin Psychiatry 60:47\u201351","journal-title":"J Clin Psychiatry"},{"key":"1418_CR28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognition in schizophrenia. Schizophr Bull 25:233\u2013256","journal-title":"Schizophr Bull"},{"key":"1418_CR29","first-page":"53","volume":"10","author":"Meltzer","year":"1975","unstructured":"Meltzer HY, Sachar EJ, Franz AG (1975) Dopamine antagonism by thioridazine in schizophrenia. Biol Psychiatry 10:53-57","journal-title":"Biol Psychiatry"},{"key":"1418_CR30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drug on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238\u2013246","journal-title":"J Pharmacol Exp Ther"},{"key":"1418_CR31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00517391","volume":"292","author":"Miller","year":"1976","unstructured":"Miller RJ, Hiley CR (1976) Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: relationship to drug induced parkinsonism. Naunyn Schmiedeberg's Arch Pharmacol 292:289\u2013293","journal-title":"s Arch Pharmacol"},{"key":"1418_CR32","first-page":"172","volume":"18","author":"Moore","year":"1975","unstructured":"Moore DF (1975) Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine. Curr Ther Res Clin Exp 18:172\u2013180","journal-title":"Curr Ther Res Clin Exp"},{"key":"1418_CR33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","volume":"355","author":"Newman-Tancredi","year":"1998","unstructured":"Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTP gammaS binding study. Eur J Pharmacol 355:245\u2013256","journal-title":"Eur J Pharmacol"},{"key":"1418_CR34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","volume":"33","author":"Nordstrom","year":"1993","unstructured":"Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227\u2013235","journal-title":"Biol Psychiatry"},{"key":"1418_CR35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/BF02246453","volume":"126","author":"Palvimaki","year":"1996","unstructured":"Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J (1996) Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology 126:234\u2013240","journal-title":"Psychopharmacology"},{"key":"1418_CR36","unstructured":"Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York"},{"key":"1418_CR37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0893-133X(88)90001-2","volume":"1","author":"Rasmussen","year":"1988","unstructured":"Rasmussen K, Aghajanian GK (1988) Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology 1:101\u2013107","journal-title":"Neuropsychopharmacology"},{"key":"1418_CR38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/sj.bjp.0702350","volume":"126","author":"Reavill","year":"1999","unstructured":"Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126:572\u2013574","journal-title":"Br J Pharmacol"},{"key":"1418_CR39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","volume":"48","author":"Rollema","year":"2000","unstructured":"Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000) 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the prefrontal cortex. Biol Psychiatry 48:229\u2013237","journal-title":"Biol Psychiatry"},{"key":"1418_CR40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0022-3565(25)11452-3","volume":"260","author":"Roth","year":"1992","unstructured":"Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260:1361\u20131365","journal-title":"J Pharmacol Exp Ther"},{"key":"1418_CR41","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"Roth","year":"1994","unstructured":"Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403\u20131410","journal-title":"J Pharmacol Exp Ther"},{"key":"1418_CR42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02311185","volume":"120","author":"Roth","year":"1995","unstructured":"Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995) D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365\u2013368","journal-title":"Psychopharmacology"},{"key":"1418_CR43","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjp.0703139","volume":"129","author":"Sakaue","year":"2000","unstructured":"Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A, Matsuda T (2000) Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129:1028\u20131034","journal-title":"Br J Pharmacol"},{"key":"1418_CR44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00380972","volume":"235","author":"Scholz","year":"1985","unstructured":"Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235:60\u201364","journal-title":"Eur Arch Psychiatr Neurol Sci"},{"key":"1418_CR45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drug: in vitro and in vivo receptor binding. Psychopharmacology 124:57\u201373","journal-title":"Psychopharmacology"},{"key":"1418_CR46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00003495-199244060-00007","volume":"44","author":"Schwartz","year":"1992","unstructured":"Schwartz JT, Brotman AW (1992) A clinical guide to antipsychotic drugs. Drugs 44:981\u2013992","journal-title":"Drugs"},{"key":"1418_CR47","first-page":"821","volume":"125","author":"Seeman","year":"1981","unstructured":"Seeman MV (1981) Pharmacological features and effects of neuroleptics. Can Med Assoc J 125: 821\u2013826","journal-title":"Can Med Assoc J"},{"key":"1418_CR48","first-page":"29","volume":"21","author":"Singh","year":"1996","unstructured":"Singh AN, Barlas C, Singh S, Franks P, Mishra RK (1996) A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatr Neurosci 21:29\u201334","journal-title":"J Psychiatr Neurosci"},{"key":"1418_CR49","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0893-133X(99)00057-3","volume":"21","author":"Sprouse","year":"1999","unstructured":"Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH (1999) Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 21:622\u2013631","journal-title":"Neuropsychopharmacology"},{"key":"1418_CR50","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0022-3565(25)39339-0","volume":"266","author":"Stockmeier","year":"1993","unstructured":"Stockmeier CA, DiCarlo JJ, Zhang YY, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374\u20131384","journal-title":"J Pharmacol Exp Ther"},{"key":"1418_CR51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244785","volume":"115","author":"Tanda","year":"1994","unstructured":"Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115:285\u2013288","journal-title":"Psychopharmacology"},{"key":"1418_CR52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0014-2999(87)90544-9","volume":"143","author":"Wander","year":"1987","unstructured":"Wander TJ, Nelson A, Okazaki H, Richelson E (1987) Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol 143:279\u2013282","journal-title":"Eur J Pharmacol"},{"key":"1418_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/syn.10111","volume":"46","author":"Yamada","year":"2002","unstructured":"Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T (2002) Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse 46:32\u201337","journal-title":"Synapse"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-003-1418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-003-1418-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-003-1418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-003-1418-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T12:19:46Z","timestamp":1749730786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-003-1418-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,28]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s00213-003-1418-x","relation":{},"ISSN":["0033-3158"],"issn-type":[{"value":"0033-3158","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3,28]]}}}